Category: Diabetes

Categories
CDE Diabetes

Practice Exam: Diabetes and MASLD (Chapter 42)

Formerly known as Non-Alcoholic Fatty Liver Disease (NAFLD), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) affects up to 70% of people with Type 2 diabetes. The 2024 Clinical Practice Guidelines Update introduces a major paradigm shift: moving from passive observation to active screening for liver fibrosis to prevent cirrhosis and liver-related mortality.

This practice exam tests your ability to apply the new nomenclature, utilize the recommended two-step screening algorithm, and select appropriate pharmacotherapy that addresses both metabolic and hepatic health.

Key Concepts Covered in This Exam:

  • New Nomenclature: Recognizing the shift from NAFLD to MASLD to more accurately reflect the pathophysiology driven by metabolic dysfunction.

  • Screening Algorithm: Mastering the two-step screening strategy for adults with Type 2 diabetes: utilizing the FIB-4 index (based on age, AST, ALT, and platelet count) as the initial triage tool every 3 years.

  • Advanced Assessment: Knowing when to refer for second-line non-invasive testing, such as Vibration Controlled Transient Elastography (VCTE/FibroScan) or the Enhanced Liver Fibrosis (ELF) test, for patients with indeterminate or high FIB-4 scores.

  • Pharmacotherapy: Identifying GLP-1 receptor agonists (semaglutide, liraglutide) and SGLT2 inhibitors as preferred agents for patients with T2D and MASLD, and the specific role of pioglitazone in improving liver histology in confirmed steatohepatitis (MASH).

  • Statin Safety: Reinforcing that statins are safe and indicated for cardiovascular risk reduction in patients with MASLD and should not be withheld due to mild liver enzyme elevations.

1. Case: A 62-year-old man with T2D, BMI 31 kg/m², and FIB-4 of 2.4 has transient elastography showing LSM of 6.5 kPa and ELF of 7.2. How should these results be interpreted?

2. What ELF (Enhanced Liver Fibrosis) score threshold indicates high risk of advanced fibrosis requiring specialist referral?

3. What negative predictive value does a FIB-4 score <1.3 have for ruling out advanced liver fibrosis?

4. What percentage of people with type 2 diabetes are estimated to have MASLD globally?

5. Which dietary pattern has shown the most consistent benefits for improving insulin resistance and reducing MASLD severity?

6. By how much does type 2 diabetes increase the risk of advanced liver fibrosis compared to the general population?

7. What is the primary determinant of adverse hepatic and non-hepatic outcomes in people living with MASLD?

8. A diabetes educator is counselling a patient about the relationship between diabetes duration and liver complications. Based on the evidence, which statement is most accurate?

9. Case: A clinical team is evaluating a 47-year-old woman with T2D who consumes 180 g of alcohol per week. She has hepatic steatosis on imaging and metabolic syndrome criteria. How should her liver disease be classified?

10. Up to what percentage of individuals with advanced liver fibrosis may have normal transaminase levels (ALT, AST)?

11. Case: A healthcare team is reviewing noninvasive tests for MASLD in their T2D population. The team discusses that diagnostic tests may have lower performance in people with T2D. What is the clinical implication?

12. Case: A patient with T2D and MASH asks about vitamin E supplementation. What should be explained?

13. What is the leading cause of death in people living with MASLD?

14. Case: A 55-year-old woman with T2D has a FIB-4 score of 3.2. What is the recommended management?

15. A policy committee is considering recommendations for MASLD screening in the T2D population. Which statement best supports the rationale for universal screening with FIB-4?

16. Case: A clinical pharmacist is reviewing the evidence for resmetirom in MASLD treatment. Based on the guidelines, what is the current status of this medication in Canada?

17. What is MetALD?

18. Case: A 55-year-old man with T2D and MASLD with F3 fibrosis needs antihyperglycemic therapy optimization. Which of the following agents may be preferentially considered?

19. What percentage of individuals with T2D have metabolic-associated steatohepatitis (MASH)?

20. Case: A patient with T2D has the following: BMI 28 kg/m², triglycerides 1.9 mmol/L, HDL-C 0.9 mmol/L (male), BP 138/86 mmHg. Which cardiometabolic criteria for MASLD evaluation does this patient meet?

21. Case: A 50-year-old woman with T2D has intermediate FIB-4 (2.1) but transient elastography is unavailable locally. What is the alternative approach?

22. A patient with T2D and MASLD asks about statin therapy. The patient has compensated cirrhosis. What is the appropriate recommendation?

23. Case: A patient with MASLD cirrhosis (F4) asks about surveillance. How often should hepatocellular carcinoma (HCC) screening be performed?

24. What minimum sustained weight loss percentage is recommended to potentially reverse liver fibrosis?

25. Case: A 58-year-old patient with T2D, MASLD, and F2 fibrosis is currently on metformin monotherapy with suboptimal glycemic control. The physician is considering adding pioglitazone. What potential benefit for MASLD may this provide?

26. What liver stiffness measurement (LSM) threshold on transient elastography indicates high risk of advanced fibrosis?

27. Case: A patient with T2D and MASLD is considering bariatric surgery. They have BMI 38 kg/m² and have been unsuccessful with lifestyle modifications. They have compensated cirrhosis. What is the most appropriate recommendation based on the guidelines?

28. What FIB-4 score threshold indicates a LOW probability of advanced liver fibrosis?

29. Which fibrosis stages are classified as “advanced fibrosis” in MASLD?

30. What is the relationship between hepatic steatosis and the development of type 2 diabetes?

31. Case: A diabetes educator is developing a screening protocol for MASLD in a diabetes clinic. The clinic has limited access to specialists and advanced testing. Based on the guidelines, what is the most appropriate first-line screening strategy?

32. Case: A 45-year-old woman with prediabetes has a FIB-4 score of 0.9. How should she be managed?

33. Case: A 48-year-old man with T2D and decompensated cirrhosis is on statin therapy. What is the appropriate action?

34. Case: A 52-year-old man with type 2 diabetes has a FIB-4 score of 1.8. What is the most appropriate next step?

35. Case: A 54-year-old patient with T2D and MASH (F2 fibrosis) has been on pioglitazone for 12 months with good glycemic control but limited weight loss (3%). The patient asks if adding a GLP-1 RA would provide additional hepatic benefits. Based on the guidelines, what is the most appropriate response?

36. Case: A patient with T2D and MASLD without obesity (BMI 23 kg/m²) asks about weight loss recommendations. What should be advised?

37. Which tests are used for HCC surveillance in patients with MASLD cirrhosis?

38. A multidisciplinary team is discussing the care of patients with T2D and MASLD. Which statement best reflects guideline recommendations for cardiovascular risk management?

39. Which laboratory values are required to calculate the FIB-4 score?

40. According to the updated nomenclature, what is the current term for the condition previously known as nonalcoholic fatty liver disease (NAFLD)?


 

Categories
CDE Diabetes

Study Guide: Diabetes and Metabolic Dysfunction-associated Steatotic Liver Disease (Chapter 42)

1. New Nomenclature & Definitions

The terminology has shifted from “Non-alcoholic” to “Metabolic” to reduce stigma and better reflect the pathophysiology.

  • MASLD (Metabolic dysfunction-associated Steatotic Liver Disease): Replaces NAFLD. Defined as hepatic steatosis with at least one cardiometabolic risk factor (Diabetes/Prediabetes, Obesity, Hypertension, Dyslipidemia) and without harmful alcohol intake.
  • MASH (Metabolic dysfunction-associated Steatohepatitis): Replaces NASH. The progressive form characterized by inflammation and hepatocyte injury (ballooning).
  • MetALD: A new category for individuals with MASLD who also consume increased alcohol (140–350 g/week for women, 210–420 g/week for men). This highlights the synergistic damage of metabolic disease and alcohol .

2. Epidemiology & Risk

  • Prevalence:
    • Type 2 Diabetes (T2D): ~70% have MASLD.
    • Type 1 Diabetes (T1D): ~22% have MASLD.
  • Primary Risk Driver: Liver Fibrosis (scarring) is the primary determinant of adverse outcomes (hepatic and non-hepatic).
  • Mortality: The leading cause of death in people with MASLD is Cardiovascular Disease (CVD), followed by extrahepatic cancers and liver-related complications.

3. Screening & Diagnosis (The FIB-4 Index)

Because steatosis is so common in T2D, screening focuses on identifying advanced fibrosis (F3–F4) rather than just fatty liver.

  • Who to Screen: All adults with Prediabetes or Type 2 Diabetes.
  • Screening Tool: Fibrosis-4 Index (FIB-4).
    • Inputs: Age, AST, ALT, Platelet Count.
  • Interpretation & Action:

    • Low Risk (FIB-4 < 1.3): Unlikely to have advanced fibrosis. Manage in primary care; repeat screening in 1–3 years.

    • Indeterminate Risk (FIB-4 1.3 – 2.67): Requires “second-line” testing (e.g., transient elastography/FibroScan® or ELF test) to clarify risk.

    • High Risk (FIB-4 > 2.67): High probability of advanced fibrosis. Refer to Hepatology.

4. Management Strategies

A. Lifestyle Interventions (Cornerstone)

  • Weight Loss:

    • 5%: Required to reduce liver fat.

    • 7-10%: Required to resolve MASH (inflammation) and improve fibrosis.

  • Diet: The Mediterranean Diet is specifically recommended to reduce liver fat and improve outcomes.

  • Alcohol: Abstinence or minimization of alcohol intake is crucial.

B. Pharmacotherapy

Agents used for diabetes can have dual benefits for the liver.

  • Pioglitazone: Improves MASH resolution and improves fibrosis scores. (Watch for weight gain/heart failure).

  • GLP-1 Receptor Agonists (Semaglutide, Liraglutide): Improve MASH resolution but have not consistently shown improvement in fibrosis stage in trials as of time of guideline developement.

  • SGLT2 Inhibitors: Reduce liver fat content and liver enzymes; effects on histology (fibrosis) are less established but they provide cardiorenal protection.

  • Statins: Safe to use in MASLD. Do not discontinue statins due to mild liver enzyme elevations; they reduce cardiovascular risk, which is the leading cause of death in this population.

C. Surgical Management

  • Bariatric (Metabolic) Surgery: Can result in resolution of MASH and improvement in fibrosis in a high percentage of patients (up to 80-90%).

5. Diabetes Canada 2025 Clinical Practice Guidelines Recommendations

Key takeaways for the exam.

  1. Screening: Screen all adults with T2D or prediabetes for MASLD with the FIB-4 Index (every 1-3 years) [Grade D, Consensus].

  2. Pathway:

    • If FIB-4 < 1.3: Manage standard CV risks [Grade C, Level 3].

    • If FIB-4 > 2.67: Refer to specialist/hepatologist [Grade C, Level 3].

  3. Lifestyle: Aim for 7-10% weight loss to improve liver fibrosis/inflammation [Grade B, Level 2].

  4. Pharmacotherapy: Consider Pioglitazone or GLP-1 RAs (Semaglutide/Liraglutide) for patients with biopsy-proven MASH or those at high risk to improve liver health [Grade A/B].

  5. Statins: Statins are safe and should be used to reduce CV risk in patients with MASLD [Grade B, Level 2].

Reference:

Kim J, Bajaj HS, Ramji A, Bemeur C, Sebastiani G. Diabetes and Metabolic Dysfunction–associated Steatotic Liver Disease in Adults: A Clinical Practice Guideline. Canadian Journal of Diabetes. 2025;49(4):222-236. doi:10.1016/j.jcjd.2025.04.003
Categories
CDE Diabetes

Flashcards: Glycemic Management in Type 1 Diabetes (Chapter 41)

This module covers the critical paradigm shifts in the management of Type 1 Diabetes (T1D) for both adults and children. These guidelines replace the previous 2018 chapters on Glycemic Management in Adults and portions of the Type 1 Diabetes in Children and Adolescents chapter.

Key Concepts Covered in These Flashcards:

  • Unified Glycemic Targets: The shift to an A1C target of <7.0% for all ages, including children, to protect brain development and reduce long-term complications.

  • Technology First: The new recommendation establishing Automated Insulin Delivery (AID) systems as the preferred treatment method for all individuals willing and able to use them.

  • Advanced Therapeutics: The role of ultrarapid and ultra-long-acting insulin analogues in minimizing hypoglycemia and improving Time in Range (TIR).

  • Adjunctive Therapies: Evidence-based guidance on the use of non-insulin agents like Metformin, GLP-1RAs, and SGLT2 inhibitors in adults.

  • Emergency Management: Updated protocols for treating hypoglycemia (including adjustments for AID users) and managing Diabetic Ketoacidosis (DKA) with fluids and subcutaneous insulin.

Categories
CDE Diabetes

Practice Exam: Glycemic Management in Type 1 Diabetes (Chapter 41)

This new “Special Article” and Clinical Practice Guideline (Chapter 41) represents a significant consolidation in the Diabetes Canada guidelines. It replaces the previous separate chapters for Adults (2018, Ch. 12) and Children/Adolescents (2018, Ch. 34).

For the CDE candidate, this chapter is high-yield. It moves away from age-stratified silos and towards a lifespan approach that prioritizes technology, mental burden reduction, and aggressive complication prevention.

Before you jump into the practice questions, here are the 5 Key Practice Changes you need to know:

  1. AID is the New Gold Standard The guidelines no longer present insulin pumps as a second-line option for specific candidates. Automated Insulin Delivery (AID) systems are now the preferred treatment method for all individuals (adults and children) to optimize glycemia and improve person-reported outcomes. If AID is not possible, CGM should be used with pump therapy or basal-bolus injections.
  2. Pediatric Targets Have Tightened Historically, A1C targets for children were higher to avoid hypoglycemia. However, new evidence links chronic hyperglycemia in young children to white matter structural changes in the brain. Consequently, the recommended A1C target for the pediatric population is now <7.0% across all age groups.
  3. “Ultra” Insulins are Preferred To minimize hypoglycemia and improve outcomes, ultra-rapid and ultra-long-acting insulin analogues should be considered in place of standard rapid- or long-acting analogues for both adults and children.
  4. Adjunctive Therapies (Non-Insulin) The guidelines now open the door for adjunctive therapies in adults, such as Metformin, GLP-1 RAs, or SGLT2 inhibitors, to help meet goals. However, this comes with strict safety warnings, particularly regarding the risk of euglycemic DKA with SGLT2i use.
  5. Managing Emergencies There are updated protocols for hypoglycemia and DKA:
    • Hypoglycemia: Intranasal glucagon is recommended for adults and children.
    • DKA: Subcutaneous insulin can be safely used to manage non-severe DKA , and fluid resuscitation in children can be more aggressive than previously feared.

Please go to Practice Exam: Glycemic Management in Type 1 Diabetes (Chapter 41) to view this quiz

Categories
CDE Diabetes

Study Guide: Glycemic Management Across the Lifespan for People With Type 1 Diabetes (2025 Update)

1. Overview & Scope

This is a major update that replaces the 2018 “Glycemic Management in Adults with Type 1 Diabetes” chapter and updates the glycemic sections of the “Type 1 Diabetes in Children and Adolescents” chapter.

  • Goal: To support individuals in living well with type 1 diabetes throughout their lifespan, balancing glycemic optimization with hypoglycemia risk and quality of life.
  • Key Shift: Universal access to advanced insulin therapies (second-generation analogues) and technologies (Automated Insulin Delivery) is advocated for all individuals.

2. Updated Terminology

The guidelines have updated the language to reflect modern clinical practice.

New TermPrevious/
Related Terms		Description
BBI (Basal Bolus Injection)MDI (Multiple Daily Injections)Subcutaneous delivery of rapid and long-acting insulin via pens/syringes.
IPT (Insulin Pump Therapy)CSII (Continuous Subcutaneous Insulin Infusion)Pump therapy without automation.
IPT + PLGSSAP + PLGS (Sensor Augmented Pump)Pump + CGM with Predictive Low Glucose Suspend (automated basal suspension).
AID (Automated Insulin Delivery)Hybrid Closed Loop / Artificial PancreasPump + CGM with automated increases, decreases, and suspensions of basal insulin (and sometimes automated boluses).

3. Glycemic Targets

  • Universal Target: An A1C target of < 7.0% is now recommended for ALL age groups, including children (previously, children had higher targets).
    • Rationale: Evidence suggests chronic hyperglycemia in young children (4–10 years) impacts brain development/cognition. New technologies (AID/CGM) make lower targets safer.
  • Person-Centered: Targets must be individualized. If <7.0% is not attainable without severe hypoglycemia or significant burden, a higher target is appropriate.

4. Insulin Therapy (Formulations)

The guidelines express a clear preference for modern analogues over older insulins to improve A1C and reduce hypoglycemia.

  • Rapid-Acting Analogues (Aspart, Lispro, Glulisine): Preferred over Regular insulin for BBI and IPT.
  • Ultrarapid-Acting Analogues (FiAsp, Lyumjev):
    • Recommendation: Should be considered in place of rapid analogues for BBI (to lower post-prandial glucose) and IPT (to improve Time in Range).
    • Timing: Ideally administered 10–20 minutes prior to meals.
  • Long-Acting Basal Analogues (Glargine U-100, Detemir): Preferred over NPH due to lower hypoglycemia risk.
  • Ultralong-Acting Basal Analogues (Glargine U-300, Degludec):
    • Recommendation: Should be considered in place of long-acting analogues to further minimize hypoglycemia (especially nocturnal) and glycemic variability.
    • Weekly Insulin: Once-weekly Icodec is not generally preferred for T1D due to a 2-fold increase in hypoglycemia risk compared to daily basal.

5. Insulin Delivery Hierarchy (The "Choice" Recommendations)

For the CDE exam, know the hierarchy of preferred treatments based on efficacy:

  1. Automated Insulin Delivery (AID):
    • Gold Standard: Preferred for ALL individuals (adults and children) willing/able to use it.
    • Benefits: Improves A1C, Time in Range (TIR), and Quality of Life; reduces hypoglycemia, diabetes distress, and sleep interruption.
  2. IPT + PLGS (Predictive Low Glucose Suspend):
    • Recommended if AID is not used, specifically to reduce hypoglycemia.
  3. Insulin Pump Therapy (IPT):
    • Preferred over BBI to improve A1C and lifestyle flexibility.
  4. Basal Bolus Injection (BBI):
    • Standard injection therapy. Use of smart apps/bolus calculators is recommended to improve outcomes.

6. Adjunctive Therapies (Adults Only)

Using non-insulin agents to help with weight, insulin dose, and glycemia.

  • Status: Conditional recommendation for Adults only. (Insufficient evidence for children).
  • Classes:
    • Metformin: Reduces weight and insulin dose; minimal A1C effect.
    • GLP-1 RAs: Reduces A1C, weight, and insulin dose. Risk: GI side effects, ketosis.
    • SGLT2 Inhibitors: Reduces A1C, weight, and variability. Risk: Euglycemic DKA and genital infections.
  • Safety: Requires careful monitoring. SGLT2i use requires the STOP DKA protocol (ketone monitoring even if glucose is normal).

7. Acute Complications: Pediatric Updates

New protocols for Hypoglycemia and DKA in children differ from historical teaching.

A. Hypoglycemia Treatment (Children/Adolescents)

  • Dose: 0.3 g/kg of carbohydrate.

    • Age < 5: 5 g

    • Age 5–10: 10 g

    • Age > 10: 15 g.

  • AID Users: May require LESS carbohydrate (e.g., 5–10 g) because the pump has already suspended insulin.
  • Severe Hypoglycemia:
    • Intranasal Glucagon: Recommended for age 4 years.
    • Injectable Glucagon: Standard for all ages; preferred over nasal for < 4 years.

B. Diabetic Ketoacidosis (DKA) Management

  • Fluids: Isotonic fluids (Normal Saline or Balanced Crystalloids) are safe. Aggressive fluid resuscitation does not increase cerebral edema risk in mild/moderate DKA.
  • Insulin: Subcutaneous insulin (rapid-acting analogues every 1–2 hours) is a safe alternative to IV insulin for mild to moderate DKA in both adults and children. This can avoid ICU admission.

8. Diabetes Canada 2025 Clinical Practice Guidelines Recommendations

Key takeaways from the “Recommendations” section (Pages 14-15).

  1. Targets: A1C < 7.0% for all ages to reduce microvascular complications, individualized based on context [Grade A/D].
  2. AID Systems: Should be used in all individuals with T1D to improve A1C, TIR, and Quality of Life [Grade A, Level 1A].
  3. Insulin Choice:
    • Ultrarapid analogues should be considered over rapid analogues to lower post-prandial glucose [Grade A, Level 1A].
    • Ultralong basal analogues should be considered over long-acting to minimize hypoglycemia [Grade C].
  4. Adjunctive Therapy (Adults): Metformin, GLP-1RA, or SGLT2i may be used in adults to achieve specific outcomes (weight/A1C) with careful safety review [Grade D, Consensus].
  5. Pediatric DKA: Use isotonic fluids [Grade B] and consider frequent subcutaneous insulin for mild/moderate cases [Grade B].

Reference:

Halperin IJ, Wicklow B, Amed S, et al. Glycemic Management Across the Lifespan for People With Type 1 Diabetes: A Clinical Practice Guideline. Canadian Journal of Diabetes. 2025;49(1):5-18. doi:10.1016/j.jcjd.2025.01.001
Categories
CDE Diabetes

Flashcards: Remission of Type 2 Diabetes (Chapter 39)

he 2022 Guidelines Update introduced a transformative concept: Type 2 diabetes is not necessarily a permanent, progressive condition. These flashcards are designed to help pharmacists and healthcare professionals quickly recall the evidence-based criteria for remission, the specific interventions (lifestyle and surgical) that drive it, and the safety protocols required for deprescribing medications.

Key Topics Covered:

  • Defining Remission: Memorizing the diagnostic criteria: an A1C <6.0% (on two tests) after at least 3 months without any glucose-lowering pharmacotherapy.

  • Intervention Strategies: Identifying Low-Energy Diets (LED) (800–1000 kcal/day, often using meal replacements) and bariatric surgery as the most effective methods for achieving remission.

  • Deprescribing Protocols: Reviewing the safety steps for stopping insulin, sulfonylureas, and SGLT2 inhibitors at the start of an intervention to prevent hypoglycemia and euglycemic DKA.

  • Terminology: Understanding why the term “remission” is used instead of “reversal” or “cure”—signaling that the risk of relapse remains and ongoing monitoring is essential.

  • Predictors of Success: Recalling that a shorter duration of diabetes (<6 years), younger age, and significant weight loss are strong predictors of achieving remission.

Categories
CDE Diabetes

Practice Exam: Remission of Type 2 Diabetes (Chapter 39)

For decades, Type 2 diabetes was viewed as a progressive, lifelong condition. The updated Clinical Practice Guidelines challenge this paradigm, confirming that remission—restoring healthy blood glucose levels without the use of antihyperglycemic medications—is a viable goal for many people.

This practice exam tests your ability to define remission, identify eligible candidates, and manage the intensive interventions (both lifestyle and surgical) required to achieve and maintain this state.

Key Concepts Covered in This Exam:

  • Defining Remission: Memorizing the specific criteria for remission: an A1C <6.0% measured at least 3 months after stopping all glucose-lowering pharmacotherapy.

  • Structured Interventions: Understanding the role of Low-Energy Diets (LED) (800–1000 kcal/day, typically using meal replacements) and bariatric surgery as the most effective evidence-based methods for achieving remission.

  • Deprescribing Safety: Applying protocols for safely tapering or stopping insulin, sulfonylureas, and SGLT2 inhibitors (to prevent euglycemic DKA) at the start of a remission intervention.

  • Terminology: Recognizing why the term “remission” is preferred over “reversal” or “cure,” emphasizing that the underlying physiology remains and hyperglycemia can return.

  • Long-Term Monitoring: Acknowledging that patients in remission still require regular screening for complications (such as retinopathy and nephropathy) and ongoing cardiovascular risk management.

Please go to Practice Exam: Remission of Type 2 Diabetes (Chapter 39) to view this quiz

Categories
CDE Diabetes

Study Guide: Remission of Type 2 Diabetes (2022 Update)

1. Definition & Terminology

This is a new topic in the guidelines. Understanding the specific definitions is crucial for the exam.

  • Definition: Remission is defined as achieving healthy glucose levels without any antihyperglycemic medications for a minimum of 3 months.

  • Why “Remission”? The terms “Reversal” or “Cure” are discouraged because glucose improvement may be temporary, and the risk of relapse remains.

  • Classification:

    • Remission to Prediabetes: A1C between 6.0% and 6.4% (off meds > 3 months).
    • Remission to Normoglycemia: A1C < 6.0% (off meds > 3 months).

Testing Protocol:

  • Primary Test: A1C is the preferred criteria.

  • Alternative: If A1C is unreliable, use Fasting Plasma Glucose (FPG) or OGTT.

  • Timing: Test at 3 months and 6 months after stopping medications or starting the intervention. If remission is achieved, monitor at least every 6 months thereafter .

2. Candidate Selection (Who is Eligible?)

Not everyone is a candidate. Remission strategies usually involve significant weight loss or surgery.

Ideal Candidates:

  • Duration: Early Type 2 diabetes (diagnosed < 6 years ago).

  • Body weight: Overweight or obesity.

  • Treatment: Not currently taking insulin.

  • Motivation: Inclination to engage in intensive weight loss behaviors.

Exclusions / Caution:

  • Comorbidities: People with established ASCVD, Heart Failure (HF), or Chronic Kidney Disease (CKD) who require organ-protective medications (SGLT2i, GLP-1 RA) should not stop these agents even if glucose normalizes.

  • Mental Health: Those with significant eating disorders or severe mental health disorders.

  • Pregnancy: Recommendations apply to non-pregnant adults.

3. Interventions for Remission

The guidelines reviewed Surgical, Behavioural, Pharmacological, and Digital interventions. Only Surgery and Health Behavioural interventions have graded recommendations.

A. Bariatric Surgery

  • Recommendation: Recommended for adults with T2D and BMI > 35 kg/m²

  • Efficacy: High remission rates (30–63% at 1–5 years).

  • Relapse: 35–50% may eventually relapse.

B. Low-Calorie Diet (The “DiRECT” Protocol)

  • Method:

    • Phase 1: Total diet replacement with low-calorie formula (800–900 kcal/day) for 3–5 months.

    • Phase 2: Structured food reintroduction (1–2 months).

      Phase 3: Weight maintenance with increased physical activity.

  • Target: Aim for > 15 kg weight loss.

  • Eligibility for this specific intervention: BMI 27–45 kg/m², T2D duration < 6 years, not on insulin.

C. Exercise + Calorie Restriction (The “U-TURN” Protocol)

  • Method: High-volume structured exercise (240–420 min/week) combined with calorie restriction.

  • Target: Modest weight loss (5–7%).

  • Eligibility: BMI > 25 kg/m², T2D duration < 10 years, A1C < 9%.

D. Pharmacological & Digital

  • Pharmacotherapy: Currently no recommendation for using meds solely to induce remission (evidence insufficient).

  • Digital: No specific app/tool recommended due to lack of RCT evidence.

4. Deprescribing & Safety

Stopping medications requires a safe, individualized approach.

  • Cardiorenal Protection: Do not stop SGLT2i or GLP-1 RA in patients with ASCVD, HF, or CKD, even if A1C is normal. This is considered “Pharmacologically-managed diabetes,” not remission.

  • Hypoglycemia: Minimize risk when tapering agents (especially insulin/sulfonylureas).

  • Blood Pressure/Lipids: Do not automatically stop statins or ACEi/ARBs. Continue if indicated for CV protection (e.g., Age > 40, established disease) .

5. Managing Expectations & Relapse

  • Shared Decision Making: Use tools like the COM-B Model (Capability, Opportunity, Motivation) and 5As (Ask, Assess, Advise, Agree, Assist) to guide conversations .

  • Relapse Management: Remission is often temporary. If weight regain > 2 kg occurs, consider “rescue” plans (e.g., brief return to meal replacements).

  • Language: Avoid terms like “Failure.” Frame remission as a journey where any weight loss/A1C reduction yields health benefits.

6. Diabetes Canada 2022 Guidelines Recommendations

Key takeaways from the “Recommendations” section (Page 759).

  1. Goal: Remission may be considered for interested individuals without eating disorders or compelling indications for specific organ-protective meds [Grade D, Consensus] .

  2. Monitoring: Test A1C every 6 months to assess for persistence or relapse.

  3. Surgery: Recommend bariatric surgery for T2D + BMI > 35 kg/m² [Grade A, Level 1A].

  4. Low-Calorie Diet: Recommend 800–850 kcal/day meal replacement diet for 3–5 months (target > 15 kg loss) for BMI 27–45, duration < 6 years, non-insulin users [Grade A, Level 1A].

  5. Exercise: Recommend intensive exercise (240–420 min/week) + diet for BMI > 25, duration < 10 years [Grade C, Level 2]

References:

Jin S, Bajaj HS, Brazeau AS, et al. Remission of Type 2 Diabetes: User’s Guide. Canadian Journal of Diabetes. 2022;46(8):762-774. doi:10.1016/j.jcjd.2022.10.005
 
MacKay D, Chan C, Dasgupta K, et al. Remission of Type 2 Diabetes. Canadian Journal of Diabetes. 2022;46(8):753-761.e8. doi:10.1016/j.jcjd.2022.10.004
Categories
CDE Diabetes

Flashcards: Type 2 Diabetes and Indigenous Peoples (Chapter 38)

Indigenous peoples in Canada face a prevalence of Type 2 diabetes that is 3 to 5 times higher than the general population, a disparity rooted in the legacy of colonization and the disruption of traditional lifestyles. These flashcards are designed to help pharmacists and healthcare professionals memorize the 2018 Clinical Practice Guidelines regarding aggressive screening protocols, the specific risks for early-onset complications, and the essential principles of cultural safety.

Key Topics Covered:

  • Screening Protocols: Recalling the recommendation to screen all Indigenous adults for Type 2 diabetes starting at age 18 (or earlier with risk factors) and repeating every 6 to 12 months.

  • Social Determinants: Understanding the impact of colonization, residential schools, and food insecurity as primary drivers of the diabetes epidemic in this population.

  • Complication Risks: Identifying end-stage renal disease (ESRD) and lower limb amputation as complications that occur more frequently and at younger ages in Indigenous patients.

  • Maternal Health: Memorizing the need for postpartum screening in women with gestational diabetes to break the cycle of intergenerational transmission.

  • Cultural Safety: Defining culturally safe care as an approach that acknowledges power imbalances, respects traditional knowledge, and requires self-reflection by the provider.

Categories
CDE Diabetes

Practice Exam: Type 2 Diabetes and Indigenous Peoples (Chapter 38)

Indigenous peoples in Canada face a disproportionate burden of Type 2 diabetes, with prevalence rates 3 to 5 times higher than the general population. The 2018 Clinical Practice Guidelines emphasize that this disparity is not inherent but is deeply rooted in the legacy of colonization, residential schools, and the resulting loss of traditional lifestyles.

This practice exam tests your ability to provide culturally safe care, apply aggressive screening protocols, and address the specific complications that affect this population at younger ages.

Key Concepts Covered in This Exam:

  • Screening Protocols: Mastering the recommendation to screen asymptomatic Indigenous adults for Type 2 diabetes starting at age 18 (or younger if risk factors are present) and repeating every 6 to 12 months.

  • Social Determinants: Recognizing colonization, residential school experiences, and food insecurity as critical determinants of health that directly impact diabetes management and outcomes.

  • Complication Risks: Understanding that Indigenous peoples experience higher rates of severe complications, particularly end-stage renal disease and lower limb amputations, often at a younger age.

  • Maternal Health: Identifying the elevated risk of diabetes in pregnancy (both pre-existing and gestational) and the critical importance of postpartum screening to prevent intergenerational transmission.

  • Cultural Safety: Applying the principles of culturally safe care, which prioritizes building trust, respecting traditional knowledge, and acknowledging the power imbalances in healthcare.

Please go to Practice Exam: Type 2 Diabetes and Indigenous Peoples (Chapter 38) to view this quiz